Skip to content

Pharma giants warn Germany's stock market stability at risk without reforms

Germany's pharma leaders sound the alarm: reliance on China and flawed laws could erode its global edge. Will Minister Warken answer their call for reform?

The image shows a poster with a variety of food items on it, including boxes and other objects. The...
The image shows a poster with a variety of food items on it, including boxes and other objects. The poster has text written on it that reads "Heidelberg - Products Alimentaires et de Régime Heidelberg".

Pharma giants warn Germany's stock market stability at risk without reforms

Five major pharmaceutical and biotechnology associations have urged Federal Health Minister Nina Warken to take immediate steps in protecting Germany's position in the global stock market. The groups warned that current policies and external pressures are threatening the sector's stability and future growth.

The associations highlighted several pressing concerns in their call to action. They pointed to Germany's growing reliance on China for essential pharmaceutical ingredients and advanced technologies. At the same time, they criticised the recent GKV Financial Stabilization Act, arguing it has introduced unnecessary uncertainty into the stock market.

They also stressed the negative effects of US trade and drug pricing policies on Germany's ability to compete. While acknowledging that the latest Pharma Dialogue had helped rebuild some trust, they insisted on deeper, long-term reforms. The groups had previously submitted proposals for structural changes but noted they had received no feedback on their evaluation.

To move forward, the associations demanded a clear roadmap for the next phase of the Pharma Strategy. They called for a coordinated effort involving all relevant federal ministries and the Chancellery. Additionally, they rejected suggestions like stricter price controls on patented drugs or tighter volume-based pricing rules, arguing these would further destabilise the stock market.

The associations have made it clear that without swift and comprehensive action, Germany risks falling behind in pharmaceutical innovation and supply chain security. They now await a formal response from Minister Warken and other key decision-makers on their proposed reforms.

Read also:

Latest